| 68.49 0.01 (0.01%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 79.99 | 1-year : | 93.43 |
| Resists | First : | 68.48 | Second : | 79.99 |
| Pivot price | 68.48 | |||
| Supports | First : | 68.47 | Second : | 68.47 |
| MAs | MA(5) : | 68.48 | MA(20) : | 68.48 |
| MA(100) : | 59.24  |
MA(250) : | 41.38 |
|
| MACD | MACD : | 0.1  |
Signal : | 0.2 |
| %K %D | K(14,3) : | 100 | D(3) : | 100 |
| RSI | RSI(14): 77.1 | |||
| 52-week | High : | 73.01 | Low : | 21.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GBT ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 68.65 - 68.99 | 68.99 - 69.26 |
| Low: | 67.51 - 67.98 | 67.98 - 68.37 |
| Close: | 67.84 - 68.54 | 68.54 - 69.12 |
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Tue, 01 Aug 2023
Syros seeking new partner for its SCD program after Pfizer ends... - Sickle Cell Disease News
Fri, 21 Jul 2023
Pfizer to end license deal with Syros for blood disorder therapies - Reuters.com
Tue, 11 Jul 2023
Sickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ ... - PR Newswire
Wed, 07 Jun 2023
Ted Love, now the chair of biotech's big trade group, talks drug ... - The Business Journals
Wed, 05 Oct 2022
Pfizer Completes Acquisition of Global Blood Therapeutics - Pfizer
Tue, 23 Aug 2022
Pfizer Bidding War With J&J Preceded Global Blood Therapeutics ... - Bloomberg
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 116.1 (%) |
| Shares Short | 9,230 (K) |
| Shares Short P.Month | 10,650 (K) |
| EPS | -4.04 |
| EPS Est Next Qtrly | -0.68 |
| EPS Est This Year | -2.45 |
| EPS Est Next Year | -2.92 |
| Book Value (p.s.) | 6.71 |
| Profit Margin | -146.9 % |
| Operating Margin | -137.4 % |
| Return on Assets (ttm) | -23.9 % |
| Return on Equity (ttm) | -124.6 % |
| Qtrly Rev. Growth | 41.2 % |
| Gross Profit (p.s.) | 2.97 |
| Sales Per Share | 3.27 |
| EBITDA (p.s.) | -4.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -249 (M) |
| Levered Free Cash Flow | -136 (M) |
| PE Ratio | -16.96 |
| PEG Ratio | -0.2 |
| Price to Book value | 10.19 |
| Price to Sales | 20.93 |
| Price to Cash Flow | -17.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|